FSD PHARMA (HUGE)
(Delayed Data from NSDQ)
$0.20 USD
+0.11 (120.75%)
Updated Aug 9, 2024 04:00 PM ET
Pre-Market: $0.20 0.00 (0.00%) 8:22 AM ET
3-Hold of 5 3
C Value B Growth NA Momentum NA VGM
Income Statements
Fiscal Year end for FSD PHARMA falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 2 |
Gross Profit | 0 | 0 | 0 | 0 | -2 |
Selling & Adminstrative & Depr. & Amort Expenses | 24 | 27 | 34 | 31 | 26 |
Income After Depreciation & Amortization | -24 | -27 | -34 | -31 | -28 |
Non-Operating Income | 6 | 1 | 0 | 2 | -11 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -18 | -27 | -34 | -28 | -39 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -18 | -27 | -34 | -28 | -39 |
Extras & Discontinued Operations | 0 | 3 | -1 | -3 | 0 |
Net Income (GAAP) | -18 | -24 | -35 | -32 | -39 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -21 | -23 | -30 | -27 | -25 |
Depreciation & Amortization (Cash Flow) | 3 | 5 | 4 | 4 | 2 |
Income After Depreciation & Amortization | -24 | -27 | -34 | -31 | -28 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 39.59 | 38.73 | 34.95 | 12.04 | 7.06 |
Diluted EPS Before Non-Recurring Items | -0.46 | -0.69 | -0.97 | -2.20 | -5.55 |
Diluted Net EPS (GAAP) | -0.46 | -0.61 | -1.01 | -2.64 | -5.56 |
Fiscal Year end for FSD PHARMA falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.26 | 1.80 | 3.32 | 8.83 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.26 | -1.80 | -3.32 | -8.83 |
Non-Operating Income | NA | 0.18 | 0.15 | 2.18 | 3.34 |
Interest Expense | NA | 0.01 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -2.09 | -1.65 | -1.13 | -5.49 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | -0.19 | -0.26 | -0.07 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.09 | -1.65 | -1.13 | -5.49 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.90 | -1.39 | -1.06 | -5.49 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 39.65 | 39.59 | 39.19 | 39.23 |
Diluted EPS Before Non-Recurring Items | NA | -0.05 | -0.04 | -0.03 | -0.14 |
Diluted Net EPS (GAAP) | NA | -0.05 | -0.03 | -0.03 | -0.14 |